

31st March 2016

Luxury & Consumer Goods

Richemont

Price CHF64.15

Cartier watch inventories buy-back likely in HK....

Fair Value CHF81 vs. CHF90 (+26%)

BUY

| | |
|----------------------------|-------------|
| Bloomberg | CFR VX |
| Reuters | CFR.VX |
| 12-month High / Low (CHF) | 86.9 / 60.8 |
| Market Cap (CHFm) | 35,924 |
| Ev (BG Estimates) (CHFm) | 27,925 |
| Avg. 6m daily volume (000) | 1,749 |
| 3y EPS CAGR | 17.1% |

| | 1 M | 3 M | 6 M | 31/12/15 |
|----------------|------|--------|--------|----------|
| Absolute perf. | 0.5% | -11.0% | -15.3% | -11.0% |
| Pers & H/H Gds | 2.4% | -0.3% | 4.0% | 0.4% |
| DJ Stoxx 600 | 2.2% | -7.2% | -1.9% | -6.7% |

| YEnd Mar. (EURm) | 03/15 | 03/16e | 03/17e | 03/18e |
|------------------|--------|--------|--------|--------|
| Sales | 10,410 | 11,160 | 11,460 | 12,290 |
| % change | | 7.2% | 2.7% | 7.2% |
| EBITDA | 3,060 | 2,660 | 2,750 | 3,125 |
| EBIT | 2,436 | 2,250 | 2,340 | 2,715 |
| % change | | -7.6% | 4.0% | 16.0% |
| Net income | 1,336 | 1,770 | 1,800 | 2,145 |
| % change | | 32.5% | 1.7% | 19.2% |

| | 03/15 | 03/16e | 03/17e | 03/18e |
|------------------|-------|--------|--------|--------|
| Operating margin | 23.4 | 20.2 | 20.4 | 22.1 |
| Net margin | 12.8 | 15.9 | 15.7 | 17.5 |
| ROE | 9.3 | 10.3 | 9.0 | 9.4 |
| ROCE | 23.3 | 18.9 | 17.7 | 19.2 |
| Gearing | -39.6 | -42.6 | -45.8 | -48.6 |

| (EUR) | 03/15 | 03/16e | 03/17e | 03/18e |
|-----------------|-------|--------|--------|--------|
| EPS | 2.39 | 3.16 | 3.21 | 3.83 |
| % change | - | 32.5% | 1.7% | 19.2% |
| P/E | 24.6x | 18.6x | 18.3x | 15.3x |
| FCF yield (%) | 4.5% | 7.5% | 8.3% | 9.4% |
| Dividends (EUR) | 1.60 | 1.85 | 2.10 | 2.20 |
| Div yield (%) | 2.7% | 3.2% | 3.6% | 3.7% |
| EV/Sales | 2.6x | 2.3x | 2.1x | 1.8x |
| EV/EBITDA | 8.9x | 9.6x | 8.6x | 7.0x |
| EV/EBIT | 11.2x | 11.4x | 10.2x | 8.0x |

Given the high level of watch inventories in HK, including for Cartier, we consider that the brand could well clean up its inventories in the trade, particularly in HK, in order to buy back slow moving watches. Although we consider this the right thing to do in the current environment, the move will have an impact on sales and EBIT margin as early as this year (end of March 2016). Consequently, we have cut our FY March 2016 and March 2017 EBIT estimates by 7%. Hence our new CHF82 FV vs CHF90 previously. We are maintaining our Buy recommendation however, given i/ still healthy momentum in jewellery sales (32% of CFR sales), ii/ the net cash position (EUR5.5bn estimated at end March 2016) that should allow management to maintain a dynamic distribution policy: dividend increase (+15% expected this year), special dividend and iii/ current upside on our FV (26%).

ANALYSIS

- Swiss watch exports reflected a fairly tough situation in January and February (-5% over the first two months) even if the decline in February (-3%) was less significant than in January (-8%). We estimate that Richemont's Q4 sales momentum should be even worse than in Q3, particularly in Europe as tourists are not yet back in France (7% of group sales, mainly via Cartier brand) and in Paris (close to 4% of Group sales). Furthermore, the situation in HK is still very challenging (exports fell 23% in 2015 and 29% over the first two months of 2016), partly due to the 3% decline in inbound Chinese tourists in 2015. We estimate that HK accounts for 20% of Cartier sales.
- Consequently, we think Cartier (45% of group sales) is likely to clean up its watch inventories particularly in HK and for slow-moving Cartier lines. HK sales were clearly affected by the 3% decline in inbound Chinese tourists. Cartier watches account for 40% of Cartier brand sales (jewellery accounts for 50%) and for around 20% of Richemont group sales. It is worth noting at this stage, that this inventories buyback (from watch retailers) should not concern "specialist watches" like Jaeger Lecoultrre or IWC, as inventory levels for these brands are not an issue. We also estimate that this decision, taken by the new management team with Cyrille Vigneron as the new Cartier CEO since January 2016, is positive for the medium term. Actually, it will allow retailers to buy new Cartier lines, but probably less high-end (fewer gold and jewelled watches and more likely steel/gold watches...).
- As such, we have adjusted our FY March 2016 sales to expect a 1% organic sales decline versus stability previously implying -6% in Q4 alone whereas we were expecting -3% previously. Inventory buybacks are set to impact sales hence this adjustment. For March 2017, we expect sales to grow no more than 2% (including a slight decline for Cartier) with a still tough H1 as inventory buybacks will affect sales, while we are more optimistic for H2 (easier comps and no further buybacks impact). Gross profit and EBIT should also be impacted by this policy. Hence our new March 2016 EBIT margin assumption of 20% (-320bp) versus 21.2% expected previously (our March 16 EBIT is cut by 7% to EUR2.25bn). We assume that the buyback and destruction of Cartier watches could have a negative impact of around EUR100m on March 2016 EBIT. Our FY March 16 adjustment implies a 490bp profitability erosion in H2 alone after -200bp in H1.

VALUATION

- Despite this significant results adjustment, we are maintaining our Buy recommendation, with a new EUR81 FV vs EUR90 previously, given, i/ still healthy momentum in jewellery sales (32% of CFR sales) and ii/ the net cash position (EUR5.5bn estimated at end March 2016) that should allow management to maintain a dynamic distribution policy: dividend increase, special dividend) even during the tough period and perhaps even more during this period iii/ current upside on our FV (26%).
- The stocks is down 11% YTD (stability for sector average) and it is trading at 11.4x on 2016 EV/EBIT, a 4% discount vs the peer average.

NEXT CATALYSTS

- FY March 2016 results to be reported on May 20th.



Analyst :
Loïc Morvan
33(0) 1 70 36 57 24
lmorvan@bryangarnier.com

Sector Team :
Nikolaas Faes
Antoine Parison
Cédric Rossi
Virginie Roumage

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

| | |
|---------|---|
| BUY | Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion. |
| NEUTRAL | Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion. |
| SELL | Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion. |

Distribution of stock ratings

BUY ratings 64%

NEUTRAL ratings 28.7%

SELL ratings 7.4%

Research Disclosure Legend

| | | | |
|----|---|--|-----|
| 1 | Bryan Garnier shareholding in Issuer | Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer"). | No |
| 2 | Issuer shareholding in Bryan Garnier | The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group. | No |
| 3 | Financial interest | A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report | No |
| 4 | Market maker or liquidity provider | A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives. | No |
| 5 | Lead/co-lead manager | In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives. | No |
| 6 | Investment banking agreement | A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services. | No |
| 7 | Research agreement | A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report. | No |
| 8 | Analyst receipt or purchase of shares in Issuer | The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares. | No |
| 9 | Remuneration of analyst | The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group. | No |
| 10 | Corporate finance client | In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months. | No |
| 11 | Analyst has short position | The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer. | No |
| 12 | Analyst has long position | The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer. | No |
| 13 | Bryan Garnier executive is an officer | A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above. | No |
| 14 | Analyst disclosure | The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report. | Yes |
| 15 | Other disclosures | Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed). | No |

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

| London | Paris | New York | Geneva | New Delhi |
|---------------------------------|---|--------------------------|--------------------|----------------------|
| Beaufort House | 26 Avenue des Champs Elysées | 750 Lexington Avenue | rue de Grenus 7 | The Imperial Hotel |
| 15 St. Botolph Street | 75008 Paris | New York, NY 10022 | CP 2113 | Janpath |
| London EC3A 7BB | Tel: +33 (0) 1 56 68 75 00 | Tel: +1 (0) 212 337 7000 | Genève 1, CH 1211 | New Delhi 110 001 |
| Tel: +44 (0) 207 332 2500 | Fax: +33 (0) 1 56 68 75 01 | Fax: +1 (0) 212 337 7002 | Tel +4122 731 3263 | Tel +91 11 4132 6062 |
| Fax: +44 (0) 207 332 2559 | Regulated by the | FINRA and SIPC member | Fax+4122731 3243 | +91 98 1111 5119 |
| Authorised and regulated by the | Financial Conduct Authority (FCA) and | | Regulated by the | Fax +91 11 2621 9062 |
| Financial Conduct Authority | the Autorité de Contrôle prudentiel et de | | FINMA | |
| (FCA) | resolution (ACPR) | | | |

Important information

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available..